MaxCyte, Inc. to present on development of novel tumor-targeted enhanced potency T cell immunotherapy at the 15th Annual Meeting of the International Society of Cellular Therapy (ISCT)

GAITHERSBURG, Md.--(BUSINESS WIRE)--MaxCyte will be presenting results on the development of an engineered tumor-targeted T cell therapy uniquely enabled by the use of MaxCyte® GT™ Flow Transfection System at the 15th Annual Meeting of the International Society of Cellular Therapy (ISCT) in San Diego. The presentation is entitled "Scalable electroporation mediates efficient RNA-CAR transfection in expanded T cells with a dependence of expression duration on intracellular activation domains" and will be presented as Poster #87 on May 5, 2009 at 5:00-6:00PM.